Menu
← Oncology Approval Tracker
FDA DECISION ·
Bortezomib for Injection
bortezomib · Fresenius Kabi
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adds a retreatment dosing regimen for multiple myeloma in the injectable bortezomib label.
LAMPGEN ANALYSIS
Why it matters
The supplement adds a dosing pathway for reusing bortezomib after a prior course.
What research teams should watch
Document prior response and the interval since treatment, and verify the retreatment schedule and last tolerated dose.
PRIMARY RECORDS